drugset / Trial / NCT00948090
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
Phase 2
Completed
207 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
Center for International Blood and Marrow Transplant Research · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study for the outcome and safety of individualized busulfan dosing with cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat Non-Hodgkin or Hodgkin's Lymphoma.
Timeline
- Start
- 2010-01
- Primary completion
- 2013-05
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 2.5 g | — |
| Background | Etoposide | Small molecule | 1400 mg/m2 | — |